Publications by authors named "Gregory Mader"

Claim this Profile
M
Mortality risk in patients with autosomal dominant polycystic kidney disease.
Deirdre Mladsi, Xiaolei Zhou, Gregory Mader, Myrlene Sanon, Jinyi Wang

BMC Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma.
Gregory Mader, Federico Ghinelli, Francesca Torelli, Chad Patel, Cristina Masseria

Expert Rev Pharmacoecon Outcomes Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price.
Deirdre Mladsi, Christine L Barnett, Gregory Mader, T Alexander Russell-Smith, Aig Unuigbe

Value Health· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L Barnett

BMC Nephrol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis